DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DIGITAL CONTENT

1 NEWS #PharmaBuzz

media
1 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1352608-82-2, Ew-7197, Ew 7197, Tew-7197, Tew 7197, Ew7197

Molecular Formula

C₂₂H₁₈FN₇

Molecular Weight

399.4 g/mol

InChI Key

FJCDSQATIJKQKA-UHFFFAOYSA-N

FDA UNII

6T4O391P5Y

Vactosertib is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. Upon oral administration, vactosertib inhibits the activity of TGFBR1 and prevents TGF-beta/TGFBR1-mediated signaling. This suppresses tumor growth in TGFBR1-overexpressing tumor cells. TGFBR1, which is overexpressed in a variety of tumor cell types, plays a key role in tumor cell proliferation. Expression of TGF-beta promotes tumor cell proliferation, enhances the migration of tumor cells and suppresses the response of the host immune system to tumor cells.

1 2D Structure

Vactosertib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-fluoro-N-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]methyl]aniline

2.1.2 InChI

InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)

2.1.3 InChI Key

FJCDSQATIJKQKA-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=NC(=CC=C1)C2=C(N=C(N2)CNC3=CC=CC=C3F)C4=CN5C(=NC=N5)C=C4

2.2 Other Identifiers

2.2.1 UNII

6T4O391P5Y

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Ew-7197

2. N-((4-((1,2,4)triazolo(1,5-a)pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline

2.3.2 Depositor-Supplied Synonyms

1. 1352608-82-2

2. Ew-7197

3. Ew 7197

4. Tew-7197

5. Tew 7197

6. Ew7197

7. Chembl3260567

8. 6t4o391p5y

9. 2-fluoro-n-[[5-(6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-imidazol-2-yl]methyl]aniline

10. N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline

11. N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo-[1,5-a]pyridin-6-yl-1h-imidazole-2-methanamine

12. N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-1h-imidazole-2-methanamine

13. N-((4-((1,2,4)triazolo(1,5-a)pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline

14. N-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1h-imidazol-2-yl]methyl]-2-fluoroaniline

15. Vactosertib [inn]

16. Vactosertib [who-dd]

17. Schembl250076

18. Unii-6t4o391p5y

19. Gtpl8107

20. Dtxsid401010181

21. Hms3674i03

22. Bcp18384

23. Ex-a1738

24. Nov-1301

25. Am9667

26. Bdbm50015639

27. Mfcd28348363

28. S7530

29. Akos027250746

30. Zinc113391423

31. Ccg-264709

32. Cs-5679

33. Db15310

34. Sb17272

35. Ncgc00386413-01

36. Ncgc00386413-02

37. Ac-29028

38. As-10150

39. Bt168124

40. Hy-19928

41. N-[[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methyl-2-pyridyl)-2-imidazolyl]methyl]-2-fluoroaniline

42. Sy235585

43. Ds-001727

44. A14213

45. Q27077252

46. 1h-imidazole-2-methanamine, N-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-(1,2,4)triazolo(1,5-a)pyridin-6-yl-

47. 1h-imidazole-2-methanamine,n-(2-fluorophenyl)-5-(6-methyl-2-pyridinyl)-4-[1,2,4]triazolo[1,5-a]pyridin-6-yl-

48. 2-fluoro-n-((4-(6-methylpyridin-2-yl)-5-((1,2,4)triazolo(1,5-a)pyridin-6-yl)-1h-imidazol-2-yl)methyl)aniline

49. N-((5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(6-methylpyridin-2-yl)-1h-imidazol-2-yl)methyl)-2-fluoroaniline

50. N-(2-fluorophenyl)-4-([1,2,4]triazolo[1,5-a]pyridine-6-yl)-5-(6-methyl-2-pyridyl)-1h-imidazole-2-methaneamine

2.4 Create Date

2012-01-23

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₁₈FN₇
Molecular Weight	399.4 g/mol
XLogP3	3.2
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	5
Exact Mass	399.16077177 g/mol
Monoisotopic Mass	399.16077177 g/mol
Topological Polar Surface Area	83.8 Å²
Heavy Atom Count	30
Formal Charge	0
Complexity	566
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

Digital Content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Vactosertib manufacturers, exporters & distributors on PharmaCompass

Vactosertib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

DIGITAL CONTENT

1 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?